<DOC>
	<DOCNO>NCT01635790</DOCNO>
	<brief_summary>The primary objective demonstrate non-inferiority bevacizumab ranibizumab treatment patient DME ( OCT central area thickness &gt; 275 μm ) determine change best-corrected visual acuity ( BCVA ) study eye baseline month 6 .</brief_summary>
	<brief_title>Comparing Effectiveness Costs Bevacizumab Ranibizumab Patients With Diabetic Macular Edema ( BRDME )</brief_title>
	<detailed_description>Objective : To compare effectiveness cost 1.25 mg bevacizumab 0.5 mg ranibizumab , give monthly intravitreal injection 6 month . It hypothesize bevacizumab non-inferior ranibizumab regard effectiveness . Study design : This randomize , control , double mask , clinical trial 246 patient seven academic trial centre The Netherlands . Study population : patient 18 year age high diabetic macular best correct visual acuity BCVA score 78 20 letter study eye . Outcomes : The primary outcome measure change best-corrected visual acuity ( BCVA ) study eye Baseline Month 6 . Secondary outcome amongst others proportion patient gain 15 letter and/or BCVA 20/40 6 month , cost cost per quality adjust life-year two treatment .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Male female patient &gt; 18 year age sign informed consent ; 2 . Patients Type 1 Type 2 diabetes mellitus ( accord American Diabetes Association World Health Organization ( WHO ) guideline ) glycosylated haemoglobin ( HbA1c ) less 12.0 % screening ( Visit 1 ) . Patients dietary , exercise and/or pharmacological program diabetes . Treatment diabetes must stable least 2 month ; 3 . Patients visual impairment due DME ( within EDTRS criterion clinically significant macular edema ) least one eye , central area thickness &gt; 275 ìm , eligible antiVEGF treatment accord investigator . If eye eligible , one bad visual acuity , assess visit 1 , select investigator study eye ; 4 . BCVA equal 24 less equal 78 letter study eye screen use ETDRS like visual acuity test chart test distance 4 meter ( approximate Snellen equivalent 20/32 20/320 ) . 1 . Women childbearing potential . 2 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive serum pregnancy test ( human chorionic gonadotropin &gt; 5 mIU/ml ) ; 3 . Inability comply study procedure ; 4 . Active intraocular inflammation ( grade + ) either eye enrolment ; 5 . Any active infection ( e.g. , conjunctivitis , keratitis , scleritis , uveitis , endophthalmitis ) either eye time enrolment ; 6 . History uveitis either eye time ; 7 . Structural damage within 600 centre macula study eye likely preclude improvement visual acuity follow resolution macular edema , include atrophy retinal pigment epithelium , subretinal fibrosis , laser scar ( ) , epiretinal membrane involve fovea organize hard exudate plaque ; 8 . Uncontrolled glaucoma study eye screening ( IOP &gt; 24 mmHg medication accord investigator 's judgment ) ; 9 . Neovascularization iris study eye ; 10 . Evidence vitreomacular traction study eye ; 11 . Active untreated proliferative diabetic retinopathy study eye ; 12 . Any intraocular surgery study eye within 3 month prior randomization ; 13 . History vitrectomy study eye regardless time prior randomization ; 14 . Planned medical surgical intervention 6 month study period ; 15 . Panretinal laser photocoagulation study eye within 3 month prior study ; 16 . Focal/grid laser photocoagulation study eye 3 month prior study entry ; 17 . Treatment antiangiogenic drug study eye ( pegaptanib sodium , anecortave acetate , bevacizumab , ranibizumab , VEGFTrap , etc . ) within 3 month prior randomization ; 18 . Use investigational drug time enrolment , within 3 month 5 halflives enrolment , whichever longer ; 19 . History intravitreal corticosteroid phakic eye within 18 month prior randomization postcataract surgery study eye ( aphakic pseudophakic , without damage posterior capsule ) within 4 month prior randomization ; 20 . Ocular condition study eye require chronic concomitant therapy topical ocular systemically administered corticosteroid ; 21 . History stroke transient ischemic attack ( TIA ) within 6 month prior enrolment ; 22 . Renal failure require dialysis renal transplant renal insufficiency creatinine level &gt; 2.0 mg/dl screening ; 23 . Blood pressure systolic &gt; 165 mm Hg diastolic &gt; 105 mmHg screen randomization ; 24 . Hypertension change antihypertensive treatment within 1 month precede randomization ; 25 . Current use likely need systemic medication know toxic lens , retina optic nerve , include deferoxamine , chloroquine/hydroxychloroquine ( Plaquenil ) , tamoxifen , phenothiazine ethambutol ; 26 . Known hypersensitivity fluorescein , ranibizumab bevacizumab component thereof drug similar chemical class ; 27 . Any type advance , severe unstable disease treatment , may interfere primary and/or secondary variable evaluation include medical condition could expect progress , recur , change extend may bias assessment clinical status patient significant degree put patient special risk ; 28 . Concomitant condition study eye would , opinion investigator , prevent improvement visual acuity study treatment ; 29 . Ocular disorder study eye may confound interpretation study result , compromise visual acuity require medical surgical intervention 6month study period , include cataract , retinal vascular occlusion , retinal detachment , macular hole , choroidal neovascularization cause ( e.g. , AMD , ocular histoplasmosis , pathologic myopia ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>diabetic macular edema</keyword>
	<keyword>randomize clinical trial</keyword>
</DOC>